Drugmakers signed deals worth at least $18 billion in combined value on Monday, the first day of the healthcare industry's ...
And for its part, GSK won't concede that Sirtris' small molecules don't bind the targets. In an e-mailed statement, Ad Rawcliffe, head of GSK's WorldWide Business Development group, says ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback